SEC annual filings · Chemicals and drugs
Which companies in chemicals and drugs have the most revenue in the SEC data we read?
In 2025, 102 companies in chemicals and drugs that have had revenue of one billion dollars or more are ranked; Johnson & Johnson reported the most, $94.2 billion. The newest annual report in the data is for the fiscal year ended .
Right now
Johnson & Johnson reported the most revenue in 2025, $94.2 billion.
102 companies in chemicals and drugs are ranked for 2025.
Share of revenueOurs
Together they reported $1.1 trillion of revenue, 4.5% of the revenue of all $25.2 trillion reported by the ranked companies.
As filed
Facts as filed with the SEC, and our arithmetic on them. Not investment advice.
Total assets are the figure the SEC data holds for the fiscal year end; a dash can mean the data holds a balance of another date.
Understanding the ranking
Where it stands today
Johnson & Johnson reported $94.2 billion, the most in 2025.
How is the ranking made?
The ranking lists companies by the revenue they filed with the SEC for their fiscal year in 2025, the largest first.
Read more
A company is in the ranking when its latest annual report shows revenue of one billion dollars or more, and stays in it afterwards. A company that has stopped filing keeps its page and is not ranked.
The numbers behind the chart
Which companies in chemicals and drugs reported the most revenue?102 companies
| Company | Rank | Symbol | Revenue | Profit or loss | Total assets |
|---|---|---|---|---|---|
| Johnson & Johnson | 1 | JNJ | $94.2B | $26.8B | $199B |
| Procter & Gamble Co | 2 | PG | $84.3B | $16.0B | – |
| Eli Lilly & Co | 3 | LLY | $65.2B | $20.6B | $112B |
| Merck & Co., Inc. | 4 | MRK | $65.0B | $18.3B | $137B |
| Pfizer Inc | 5 | PFE | $62.6B | $7.77B | $208B |
| AbbVie Inc. | 6 | ABBV | $61.2B | $4.23B | $134B |
| Bristol-Myers Squibb Co | 7 | BMY | $48.2B | $7.05B | $90.0B |
| Abbott Laboratories | 8 | ABT | $44.3B | $6.52B | $86.7B |
| DOW Inc. | 9 | DOW | $40.0B | – | $58.5B |
| Amgen Inc | 10 | AMGN | $36.8B | $7.71B | $90.6B |
| Linde plc | 11 | LIN | $34.0B | $6.90B | $86.8B |
| LyondellBasell Industries N.V. | 12 | LYB | $30.2B | −$738M | $34.0B |
| Gilead Sciences, Inc. | 13 | GILD | $29.4B | $8.51B | $59.0B |
| Colgate-Palmolive Co | 14 | CL | $20.4B | $2.13B | $16.3B |
| Teva Pharmaceutical Industries Ltd | 15 | TEVA | $17.3B | $1.41B | $40.7B |
| Ecolab Inc. | 16 | ECL | $16.1B | $2.08B | $24.7B |
| PPG Industries Inc | 17 | PPG | $15.9B | $1.58B | $22.1B |
| Kenvue Inc. | 18 | KVUE | $15.1B | $1.47B | $27.1B |
| Regeneron Pharmaceuticals, Inc. | 19 | REGN | $14.3B | $4.50B | $40.6B |
| Estee Lauder Companies Inc | 20 | EL | $14.3B | −$1.13B | – |
| Viatris Inc | 21 | VTRS | $14.3B | – | $37.2B |
| Mosaic Co | 22 | MOS | $12.1B | $541M | $24.5B |
| Air Products & Chemicals, Inc. | 23 | APD | $12.0B | −$395M | – |
| Vertex Pharmaceuticals Inc | 24 | VRTX | $12.0B | $3.95B | $25.6B |
| Westlake Corp | 25 | WLK | $11.2B | −$1.51B | $20.0B |
Show 77 more rows
| Company | Rank | Symbol | Revenue | Profit or loss | Total assets |
|---|---|---|---|---|---|
| International Flavors & Fragrances Inc | 26 | IFF | $10.9B | – | $25.5B |
| Bausch Health Companies Inc. | 27 | BHC | $10.3B | $157M | $26.4B |
| Biogen Inc. | 28 | BIIB | $9.89B | $1.29B | $29.4B |
| Celanese Corp | 29 | CE | $9.54B | −$1.17B | $21.7B |
| Zoetis Inc. | 30 | ZTS | $9.47B | $2.67B | $15.5B |
| Eastman Chemical Co | 31 | EMN | $8.75B | $474M | $14.9B |
| RPM International Inc | 32 | RPM | $7.86B | $662M | – |
| Clorox Co | 33 | CLX | $7.10B | $824M | – |
| CF Industries Holdings, Inc. | 34 | CF | $7.08B | – | $14.1B |
| DuPont de Nemours, Inc. | 35 | DD | $6.85B | $88.0M | $21.6B |
| Olin Corp | 36 | OLN | $6.78B | −$101M | $7.33B |
| Organon & Co. | 37 | OGN | $6.22B | $187M | $12.9B |
| Church & Dwight Co Inc | 38 | CHD | $6.20B | $737M | $8.91B |
| Coty Inc. | 39 | COTY | $5.89B | −$381M | – |
| Chemours Co | 40 | CC | $5.81B | −$386M | $7.38B |
| Huntsman Corp | 41 | HUN | $5.68B | −$284M | $7.01B |
| Sealed Air Corp | 42 | – | $5.36B | $506M | $7.01B |
| BeOne Medicines Ltd. | 43 | ONC | $5.34B | $287M | $8.19B |
| Albemarle Corp | 44 | ALB | $5.14B | −$511M | $16.4B |
| Axalta Coating Systems Ltd. | 45 | AXTA | $5.12B | $379M | $7.60B |
| Elanco Animal Health Inc | 46 | ELAN | $4.71B | −$232M | $13.4B |
| IDEXX Laboratories Inc | 47 | IDXX | $4.30B | $1.06B | $3.35B |
| Jazz Pharmaceuticals plc | 48 | JAZZ | $4.27B | −$356M | $11.7B |
| Perrigo Co plc | 49 | PRGO | $4.25B | −$1.43B | $8.54B |
| Union Carbide Corp | 50 | – | $3.99B | $560M | $4.52B |
| Solstice Advanced Materials Inc. | 51 | SOLS | $3.89B | $237M | $5.67B |
| Alnylam Pharmaceuticals, Inc. | 52 | ALNY | $3.71B | $314M | $4.97B |
| Cabot Corp | 53 | CBT | $3.71B | $331M | – |
| Fuller H B Co | 54 | FUL | $3.47B | $152M | $5.18B |
| FMC Corp | 55 | FMC | $3.47B | −$2.24B | $9.69B |
| Scotts Miracle-Gro Co | 56 | SMG | $3.41B | $145M | – |
| Avient Corp | 57 | AVNT | $3.26B | $81.9M | $6.03B |
| BioMarin Pharmaceutical Inc | 58 | BMRN | $3.22B | $349M | $7.59B |
| United Therapeutics Corp | 59 | UTHR | $3.18B | $1.33B | $7.88B |
| Amneal Pharmaceuticals, Inc. | 60 | AMRX | $3.02B | $72.1M | $3.68B |
| Trinseo plc | 61 | TSEOQ | $2.97B | −$546M | $2.28B |
| Tronox Holdings plc | 62 | TROX | $2.90B | −$470M | $6.22B |
| Neurocrine Biosciences Inc | 63 | NBIX | $2.86B | $479M | $4.63B |
| QuidelOrtho Corp | 64 | QDEL | $2.73B | – | $5.77B |
| NewMarket Corp | 65 | NEU | $2.73B | $419M | $3.49B |
| Element Solutions Inc | 66 | ESI | $2.55B | $191M | $5.10B |
| Royalty Pharma plc | 67 | RPRX | $2.38B | $771M | $19.6B |
| Stepan Co | 68 | SCL | $2.33B | $46.9M | $2.36B |
| Exelixis, Inc. | 69 | EXEL | $2.32B | $783M | $2.84B |
| Edgewell Personal Care Co | 70 | EPC | $2.22B | $25.4M | – |
| Sarepta Therapeutics, Inc. | 71 | SRPT | $2.20B | −$713M | $3.35B |
| Green Plains Inc. | 72 | GPRE | $2.09B | −$121M | $1.58B |
| Qiagen N.V. | 73 | QGEN | $2.09B | $425M | $6.28B |
| Valhi Inc | 74 | VHI | $2.08B | −$57.6M | $2.63B |
| Minerals Technologies Inc | 75 | MTX | $2.07B | −$18.4M | $3.47B |
| Moderna, Inc. | 76 | MRNA | $1.94B | −$2.82B | $12.3B |
| Hexcel Corp | 77 | HXL | $1.89B | $109M | $2.70B |
| Kronos Worldwide Inc | 78 | KRO | $1.86B | −$111M | $1.82B |
| Orion S.A. | 79 | OEC | $1.81B | −$70.0M | $1.91B |
| Innospec Inc. | 80 | IOSP | $1.78B | – | $1.83B |
| PTC Therapeutics, Inc. | 81 | PTCT | $1.73B | $683M | $2.90B |
| e.l.f. Beauty, Inc. | 82 | ELF | $1.64B | $26.3M | – |
| Sensient Technologies Corp | 83 | SXT | $1.61B | $134M | $2.24B |
| Lantheus Holdings, Inc. | 84 | LNTH | $1.54B | $234M | $2.23B |
| AdvanSix Inc. | 85 | ASIX | $1.52B | $49.3M | $1.71B |
| Interparfums Inc | 86 | IPAR | $1.49B | $208M | $1.59B |
| Alkermes plc. | 87 | ALKS | $1.48B | $242M | $2.49B |
| Keenova Therapeutics plc | 88 | – | $1.43B | −$490M | $5.63B |
| Halozyme Therapeutics, Inc. | 89 | HALO | $1.40B | $317M | $2.53B |
| Phibro Animal Health Corp | 90 | PAHC | $1.30B | $48.3M | – |
| Curaleaf Holdings, Inc. | 91 | CURLF | $1.27B | −$231M | $2.85B |
| Indivior Pharmaceuticals, Inc. | 92 | INDV | $1.24B | $210M | $1.20B |
| Bio-Techne Corp | 93 | TECH | $1.22B | $73.4M | – |
| Trulieve Cannabis Corp. | 94 | TRLV | $1.18B | −$116M | $2.70B |
| Ingevity Corp | 95 | NGVT | $1.17B | −$167M | $1.65B |
| Westlake Chemical Partners LP | 96 | WLKP | $1.17B | $48.7M | $1.26B |
| Novavax Inc | 97 | NVAX | $1.12B | $440M | $1.18B |
| Prestige Consumer Healthcare Inc. | 98 | PBH | $1.09B | $190M | – |
| CSW Industrials, Inc. | 99 | CSW | $1.08B | $112M | – |
| Acadia Pharmaceuticals Inc | 100 | ACAD | $1.07B | $391M | $1.56B |
| Balchem Corp | 101 | BCPC | $1.04B | $155M | $1.69B |
| Apellis Pharmaceuticals, Inc. | 102 | – | $1.00B | $22.4M | $1.08B |
The table scrolls sideways; the first column stays in place.
What does the ranking leave out, and where is it from?Limits and source
What this number cannot tell you
- Only companies with a revenue figure for the ranking year that passes our checks are ranked, the largest first; equal figures share a rank.
- A company's figures are its own. A company that files together with a parent or a subsidiary is ranked on its own figure, so the same business can appear twice, and a sum of revenue counts it twice.
- Total assets are shown only when the SEC data dates them within ten days of the fiscal year end, and profit only when its period ends within sixty days of it.
- A dash is a gap. Either the company did not report that figure for that year, the figure failed one of our checks and is not shown, or the SEC data holds it for another date or period than the year asks for. The dash says which when it is pointed at.
Observed .
Page updated